| Balance Sheets | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 938,944 | 631,908 | 1,087,720 | 950,052 |
| Financial royalty assets | 860,073 | 842,938 | 716,559 | 765,773 |
| Available for sale debt securities | 16,100 | 13,200 | 12,100 | 48,500 |
| Other royalty income receivable | 28,901 | 27,743 | 23,785 | 24,901 |
| Other current assets | 5,519 | 4,452 | 3,079 | 4,969 |
| Total current assets | 1,849,537 | 1,520,241 | 1,843,243 | 1,794,195 |
| Financial royalty assets, net | 15,763,674 | 15,134,291 | 15,032,015 | 14,968,074 |
| Equity securities | 129,393 | 110,529 | 141,083 | 228,867 |
| Available for sale debt securities | 302,500 | 271,900 | 219,000 | 657,300 |
| Equity method investments | 290,957 | 275,914 | 336,208 | 351,017 |
| Goodwill | 924,634 | 924,634 | - | - |
| Other assets | 86,585 | 85,491 | 36,707 | 42,789 |
| Total assets | 19,347,280 | 18,323,000 | 17,608,256 | 18,042,242 |
| Distributions payable to legacy non-controlling interests | - | - | - | 79,149 |
| Distributions payable to non-controlling interests | 77,222 | 98,197 | 108,796 | - |
| Accounts payable and accrued liabilities | 41,415 | 20,209 | 37,630 | 22,055 |
| Interest payable | 29,044 | 85,609 | 19,221 | 38,412 |
| Current portion of long-term debt | 380,000 | 999,436 | 998,605 | 996,942 |
| Other current liabilities | 3,121 | 3,075 | 18,600 | 31,200 |
| Total current liabilities | 530,802 | 1,206,526 | 1,182,852 | 1,167,758 |
| Long-term debt | 8,565,735 | 7,003,063 | 6,618,847 | 6,610,437 |
| Accrued compensation liabilities | 502,938 | 467,143 | - | - |
| Other liabilities | 126,944 | 143,328 | 17,900 | 5,580 |
| Total liabilities | 9,726,419 | 8,820,060 | 7,819,599 | 7,783,775 |
| Common stock-Common Class A | 44 | 44 | 43 | 45 |
| Common stock-Common Class B | 0 | 0 | 0 | 0 |
| Common stock-Class RRedeemable Stock | 63 | 63 | 63 | 63 |
| Additional paid-in capital | 4,112,538 | 4,127,665 | 4,210,531 | 4,107,742 |
| Retained earnings | 2,304,314 | 2,222,750 | 2,480,664 | 2,764,685 |
| Non-controlling interests | 3,206,513 | 3,155,030 | 3,100,010 | 3,388,589 |
| Treasury interests | 2,611 | 2,612 | 2,654 | 2,657 |
| Total shareholders equity | 9,620,861 | 9,502,940 | 9,788,657 | 10,258,467 |
| Total liabilities and shareholders equity | 19,347,280 | 18,323,000 | 17,608,256 | 18,042,242 |
Royalty Pharma plc (RPRX)
Royalty Pharma plc (RPRX)